References
- Cohen JP, Felix AE, Riggs K, Gupta A. Barriers to market uptake of biosimilars in the US. GaBi J. 2014;3(3):107–114.
- Simoens S. Biosimilar medicines and cost-effectiveness. Clinicoecon Outcomes Res. 2011;3:29–36.
- Simon F. Market access for biopharmaceuticals: new challenges. Health Aff (Millwood). 2006;25(5):1363–1370.
- Committee for Medicinal Products for Human Use. Guideline on Similar Biological Medicinal Products containing Monoclonal Antibodies. London: European Medicines Agency; 2010. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/11/WC500099361.pdf. Accessed December 2, 2014.
- Herper M. The world’s most expensive drugs [webpage on the Internet]. Forbes.com; 2010. Available from: http://www.forbes.com/2010/02/19/expensive-drugs-cost-business-healthcare-rare-diseases.html. Accessed December 3, 2014.
- US$67 billion worth of biosimilar patents expiring before 2020 [webpage on the Internet]. GaBi Online; 2012 [updated January 20, 2014]. Available from: http://www.gabionline.net/Biosimilars/General/US-67- billion-worth-of-biosimilar-patents-expiring-before-2020. Accessed December 2, 2014.
- European public assessment reports [webpage on the Internet]. London: European Medicines Agency; 2014. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=WC0b01ac058001d124&searchTab=searchByAuthType&alreadyLoaded=true&isNewQuery=true&status=Authorised&keyword=Enter+keywords&searchType=name&taxonomyPath=&treeNumber=&searchGenericType=biosimilars&genericsKeywordSearch=Submit. Accessed December 3, 2014.
- Canada’s biosimilar portal [webpage on the Internet]. Toronto: Gowlings; 2014. Available from: http://www.biosimilars.ca/. Accessed December 2, 2014.
- Crommelin D, Bermejo T, Bissig M, et al. Pharmaceutical evaluation of biosimilars: important differences from generic low-molecular-weight pharmaceuticals. Eur J Hosp Pharm Sci. 2005;11(1):11–17.
- Weise M, Kurki P, Wolff-Holz E, Bielsky MC, Schneider CK. Biosimilars: the science of extrapolation. Blood. 2014;124(22):3191–3196.
- Schneider CK. Biosimilars in rheumatology: the wind of change. Ann Rheum Dis. 2013;72(3):315–318.
- Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol. 2011;29(4):310–312.
- Scott BJ, Klein AV, Wang J. Biosimilar monoclonal antibodies: A Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation. J Clin Pharmacol. 2015;55(Suppl 3):S123–S132.
- Committee for Medicinal Products for Human Use. Guideline on Immunogenicity Assessment of Monoclonal Antibodies Intended for In Vivo Clinical Use. London: European Medicines Agency; 2010 [updated May 24, 2012]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128688.pdf. Accessed December 2, 2014.
- Committee for Medicinal Products for Human Use. Guideline on Similar Biological Medicinal Products Containing Monoclonal Antibodies – Non-Clinical and Clinical Issues. London: European Medicines Agency; 2010 [updated May 30, 2012]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdf. Accessed December 2, 2014.
- Feagan BG, Choquette D, Ghosh S, et al. The challenge of indication extrapolation for infliximab biosimilars. Biologicals. 2014;42(4):177–183.
- Health Products and Food Branch, Health Canada. Guidance for sponsors: information and submission requirements for subsequent entry biologics (SEBs) [webpage on the Internet]. Ottawa: Health Canada; 2010. Available from: http://www.hc-sc.gc.ca/dhp-mps/brgtherap/applic-demande/guides/seb-pbu/seb-pbu_2010-eng.php. Accessed December 2, 2014.
- US Food and Drug Administration. Guidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product (Draft Guidance). Rockville, MD; US Food and Drug Administration; 2012. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf. Accessed December 2, 2014.
- Klein AV, Wang J, Bedford P. Subsequent entry biologics (biosimilars) in Canada: approaches to interchangeability and the extrapolation of indications and uses. GaBi J. 2014;3(3):150–154.
- Committee for Medicinal Products for Human Use. Inflectra Assessment Report. London: European Medicines Agency; 2013. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002778/WC500151490.pdf. Accessed December 2, 2014.
- Danese S, Gomollon F; Governing Board and Operational Board of ECCO. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis. 2013;7(7):586–589.
- Weise M, Bielsky MC, De Smet K, et al. Biosimilars: what clinicians should know. Blood. 2012;120(26):5111–5117.
- Ebbers HC. Biosimilars: in support of extrapolation of indications. J Crohns Colitis. 2014;8(5):431–435.
- Griffith N, McBride A, Stevenson JG, Green L. Formulary selection criteria for biosimilars: considerations for US health-system pharmacists. Hosp Pharm. 2014;49(9):813–825.
- Kang YS, Moon HH, Lee SE, Lim YJ, Kang HW. Clinical experience of the use of CT-P13, a biosimilar to infliximab in patients with inflammatory bowel disease: a case series. Dig Dis Sci. Epub October 14, 2014.
- Mozaffari S, Nikfar S, Abdolghaffari AH, Abdollahi M. New biologic therapeutics for ulcerative colitis and Crohn’s disease. Expert Opin Biol Ther. 2014;14(5):583–600.
- Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72(10):1613–1620.
- Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72(10):1605–1612.
- Brinks V. Immunogenicity of biosimilar monoclonal antibodies. GaBI J. 2013;2(4):188–193.
- Remicade® Highlights of Prescribing Information [prescribing information]. Horsham, PA: Janssen Biotech, Inc.; 2013 [revised November 2013]. Available from: http://www.remicade.com/shared/product/remicade/prescribing-information.pdf. Accessed December 2, 2014.
- Gascón P, Tesch H, Verpoort K, et al. Clinical experience with Zarzio® in Europe: what have we learned? Support Care Cancer. 2013;21(10):2925–2932.
- Olry de Labry A, Giménez E, Lindner L, García L, Espín J, Rovira J. Biosimilars in the European market. GaBI J. 2013;2(1):30–35.
- Brodszky V, Baji P, Balogh O, Péntek M. Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries. Eur J Health Econ. 2014;15(Suppl 1):S65–S71.
- Sandoz: Pioneer and global leader in biosimilars [webpage on the Internet]. Sandoz Biopharmaceuticals. Available from: http://www.sandoz-biosimilars.com/aboutus/biosimilars_at_sandoz.shtml. Accessed December 2, 2014.